EGFR and non-small cell lung carcinoma: First generation EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib and erlotinib or second-generation molecules such as afatinib and dacomitinib are effective for the treatment of EGFR-mutated NSCLC, mainly in patients with EGFR exon 19 deletions or an exon 21 L858R mutation.